Serum Biomarker Profile Including CCL1, CXCL10, VEGF, and Adenosine Deaminase Activity Distinguishes Active From Remotely Acquired Latent Tuberculosis.
Adenosine Deaminase
/ blood
Adult
Biomarkers
/ blood
Case-Control Studies
Chemokine CCL1
/ blood
Chemokine CXCL10
/ blood
Cohort Studies
Cross-Sectional Studies
Female
Humans
Immunologic Tests
Latent Tuberculosis
/ blood
Logistic Models
Male
Middle Aged
Overtreatment
/ prevention & control
Sensitivity and Specificity
Vascular Endothelial Growth Factor A
/ blood
Young Adult
CCL1
CXCL10 (IP-10)
active tuberculosis (ATB)
adenosine deaminase activity (ADA)
biomarker
diagnosis
latent tuberculosis infection (LTBI)
vascular endothelial growth factor (VEGF)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
15
06
2021
accepted:
15
09
2021
entrez:
25
10
2021
pubmed:
26
10
2021
medline:
12
1
2022
Statut:
epublish
Résumé
There is an urgent medical need to differentiate active tuberculosis (ATB) from latent tuberculosis infection (LTBI) and prevent undertreatment and overtreatment. The aim of this study was to identify biomarker profiles that may support the differentiation between ATB and LTBI and to validate these signatures. The discovery cohort included adult individuals classified in four groups: ATB (n = 20), LTBI without prophylaxis (untreated LTBI; n = 20), LTBI after completion of prophylaxis (treated LTBI; n = 20), and healthy controls (HC; n = 20). Their sera were analyzed for 40 cytokines/chemokines and activity of adenosine deaminase (ADA) isozymes. A prediction model was designed to differentiate ATB from untreated LTBI using sparse partial least squares (sPLS) and logistic regression analyses. Serum samples of two independent cohorts (national and international) were used for validation. sPLS regression analyses identified C-C motif chemokine ligand 1 (CCL1), C-reactive protein (CRP), C-X-C motif chemokine ligand 10 (CXCL10), and vascular endothelial growth factor (VEGF) as the most discriminating biomarkers. These markers and ADA(2) activity were significantly increased in ATB compared to untreated LTBI (p ≤ 0.007). Combining CCL1, CXCL10, VEGF, and ADA2 activity yielded a sensitivity and specificity of 95% and 90%, respectively, in differentiating ATB from untreated LTBI. These findings were confirmed in the validation cohort including remotely acquired untreated LTBI participants. The biomarker signature of CCL1, CXCL10, VEGF, and ADA2 activity provides a promising tool for differentiating patients with ATB from non-treated LTBI individuals.
Identifiants
pubmed: 34691031
doi: 10.3389/fimmu.2021.725447
pmc: PMC8529994
doi:
Substances chimiques
Biomarkers
0
CCL1 protein, human
0
CXCL10 protein, human
0
Chemokine CCL1
0
Chemokine CXCL10
0
VEGFA protein, human
0
Vascular Endothelial Growth Factor A
0
Adenosine Deaminase
EC 3.5.4.4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
725447Informations de copyright
Copyright © 2021 Delemarre, van Hoorn, Bossink, Drylewicz, Joosten, Ottenhoff, Akkerman, Goletti, Petruccioli, Navarra, van den Broek, Paardekooper, van Haeften, Koenderman, Lammers, Thijsen, Hofland and Nierkens.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer HD declared a past co-authorship with the authors SJ and TO to the handling editor.
Références
Jundishapur J Microbiol. 2015 Mar 21;8(3):e21760
pubmed: 25861440
Tuberculosis (Edinb). 2017 Sep;106:62-72
pubmed: 28802407
Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):1120-2
pubmed: 10988140
Nat Med. 2011 Mar;17(3):372-6
pubmed: 21336285
Clin Infect Dis. 2017 Jan 15;64(2):111-115
pubmed: 28052967
J Res Med Sci. 2013 Mar;18(3):252-4
pubmed: 23930125
Eur Respir J. 2016 Dec;48(6):1751-1763
pubmed: 27836953
Lancet Infect Dis. 2017 Dec;17(12):1285-1292
pubmed: 28847636
J Clin Lab Anal. 1999;13(5):209-12
pubmed: 10494128
Respirology. 2000 Dec;5(4):321-4
pubmed: 11192541
Respirology. 2018 May;23(5):455-466
pubmed: 29457312
PLoS One. 2019 Dec 10;14(12):e0225556
pubmed: 31821340
Int J Tuberc Lung Dis. 2011 Dec;15(12):1567-72
pubmed: 22005110
Cochrane Database Syst Rev. 2014 Jan 21;(1):CD009593
pubmed: 24448973
BMC Infect Dis. 2016 Jun 10;16:265
pubmed: 27287260
Int J Med Microbiol. 2019 Jul;309(5):299-306
pubmed: 31147175
Diagn Microbiol Infect Dis. 2014 May;79(1):102-7
pubmed: 24629577
Sci Transl Med. 2019 Oct 23;11(515):
pubmed: 31645455
J Infect. 2015 Apr;70(4):346-55
pubmed: 25452040
Diagn Microbiol Infect Dis. 2016 Oct;86(2):169-71
pubmed: 27431433
J Infect. 2015 Dec;71(6):696-8
pubmed: 26271898
PLoS Med. 2016 Oct 25;13(10):e1002152
pubmed: 27780211
Eur Respir J. 2019 Sep 12;54(3):
pubmed: 31515266
Clin Diagn Lab Immunol. 2003 Jan;10(1):133-9
pubmed: 12522051
J Clin Invest. 2018 May 1;128(5):1837-1851
pubmed: 29461976
PLoS One. 2015 Dec 16;10(12):e0144705
pubmed: 26674517
Thorax. 2016 Sep;71(9):785-94
pubmed: 27146200
J Immunol Methods. 2005 May;300(1-2):124-35
pubmed: 15896801
Tuberc Respir Dis (Seoul). 2017 Jan;80(1):77-82
pubmed: 28119750
Respir Med. 2002 Aug;96(8):607-10
pubmed: 12206153
PLoS Pathog. 2016 Jun 15;12(6):e1005687
pubmed: 27304615
Front Immunol. 2021 Feb 25;12:639174
pubmed: 33717190
Anal Biochem. 1990 Jun;187(2):268-72
pubmed: 2382828
J Rheumatol Suppl. 2014 May;91:11-6
pubmed: 24788995
Multidiscip Respir Med. 2014 Mar 06;9(1):12
pubmed: 24602306
PLoS Med. 2019 Apr 16;16(4):e1002781
pubmed: 30990820
Eur Respir J. 2014 May;43(5):1472-86
pubmed: 24311770
J Leukoc Biol. 2010 Aug;88(2):279-90
pubmed: 20453107
Nat Rev Immunol. 2017 Nov;17(11):691-702
pubmed: 28736436
J Infect. 2013 Jun;66(6):475-86
pubmed: 23462597
Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):2950-4
pubmed: 1557400
Eur Rev Med Pharmacol Sci. 2015 Nov;19(22):4411-8
pubmed: 26636531
Annu Rev Immunol. 2005;23:1-21
pubmed: 15771564
Paediatr Respir Rev. 2007 Jun;8(2):124-33
pubmed: 17574156
Int J Tuberc Lung Dis. 2016 Nov;20(11):1554-1561
pubmed: 27776600
Front Immunol. 2020 Sep 10;11:2006
pubmed: 33013856
J Clin Lab Anal. 2001;15(5):236-8
pubmed: 11574950
Infect Dis (Lond). 2018 Jun;50(6):479-482
pubmed: 29334817
Front Immunol. 2018 Oct 23;9:2427
pubmed: 30405622
Eur J Immunol. 2013 Jun;43(6):1568-77
pubmed: 23456989
Front Immunol. 2021 Feb 26;12:607827
pubmed: 33717089
Clin Infect Dis. 2015 Feb 1;60(3):432-7
pubmed: 25362202
Nat Med. 2003 Jun;9(6):669-76
pubmed: 12778165
Adv Exp Med Biol. 2013;783:121-40
pubmed: 23468107
J Infect. 2014 Dec;69(6):533-45
pubmed: 24975174
Tuberculosis (Edinb). 2016 Mar;97:108-17
pubmed: 26980502
Tuberculosis (Edinb). 2013 Mar;93(2):155-66
pubmed: 23332142
Int J Infect Dis. 2012 Dec;16(12):e855-9
pubmed: 22959355
Eur Respir J. 2020 Mar 5;55(3):
pubmed: 31949119
Eur J Immunol. 2010 Aug;40(8):2211-20
pubmed: 20540114
BMC Infect Dis. 2016 Mar 12;16:123
pubmed: 26968508
Eur Respir J. 2019 Sep 12;54(3):
pubmed: 31221810